LGI1 and glioma: Patients who test positive for VGKCC antibodies are further subdivided into those with anti‐leucine‐rich glioma inactivated (anti‐LGI‐1) encephalitis (who present with limbic symptoms), anti‐contactin‐associated protein‐like 2 (anti CASPR‐2) (who present with both central and peripheral symptoms) and a third group who do not have antibodies against LGI‐1 or CASPR‐2 and who present with heterogeneous symptoms (Bastiaansen, van Sonderen, & Titulaer, 2017).